A comparative assessment of neutropenia events, healthcare resource use, and costs among patients treated with long-acting granulocyte-colony stimulating factor in Germany

被引：0
|
作者：
Link, H. [1 ]
Thompson, S. F. [2 ]
Tian, M. [3 ]
Meise, D. [4 ]
Haas, J. S. [4 ]
Maas, C. [4 ]
Dimitrov, S. [5 ]
机构：
[1] Private Practice Haematol & Oncol, Haematol & Oncol, Kaiserslautern, Germany
[2] TEVA Pharmaceut, Oncol, Parsippany, NJ USA
[3] TEVA Pharmaceut, Oncol, W Chester, PA USA
[4] Xcenda GmbH, Oncol, Hannover, Germany
[5] TEVA Pharmaceut, Oncol, Amsterdam, Netherlands
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1678
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1706P
引用
收藏
页码：S1189 / S1189
页数：1
相关论文
共 48 条
  • [31] Pooled efficacy analysis from two phase 3 studies in patients receiving eflapegrastim, a novel, long-acting granulocyte-colony stimulating factor, following TC for early-stage breast cancer
    Schwartzberg, Lee S.
    Bhat, Gajanan
    Restrepo, Alvaro
    Hlalah, Osama
    Mehmi, Inderjit
    Moon, Yong Wha
    Baek, Seungjae
    Chawla, Shanta
    Lebel, Francois
    Cobb, Patrick Wayne
    CANCER RESEARCH, 2021, 81 (04)
  • [32] Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy
    Jeon, Ye Won
    Lim, Seung Taek
    Gwak, Hongki
    Park, Seon Young
    Shin, Juhee
    Han, Hye Sug
    Suh, Young Jin
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2021, 100 (02) : 59 - 66
  • [33] Use of Granulocyte Colony-Stimulating Factor and Neutropenic Events among Breast Cancer and Non-Hodgkin's Lymphoma Patients
    Lin, Wan-Ting
    Wen, Tsun-Jen
    Chiang, Shao-Chin
    Shen, Li-Jiuan
    Hsiao, Fei-Yuan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 243 - 244
  • [34] 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
    Aapro, M. S.
    Bohlius, J.
    Cameron, D. A.
    Dal Lago, Lissandra
    Donnelly, J. Peter
    Kearney, N.
    Lyman, G. H.
    Pettengell, R.
    Tjan-Heijnen, V. C.
    Walewski, J.
    Weber, Damien C.
    Zielinski, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (01) : 8 - 32
  • [35] Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation
    Danylesko, Ivetta
    Sareli, Rina
    Varda-Bloom, Nira
    Yerushalmi, Ronit
    Shem-Tov, Noga
    Magen, Hila
    Shimoni, Avichai
    Nagler, Arnon
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 114 (03) : 363 - 372
  • [36] Long-acting granulocyte colony-stimulating factor pegfilgrastim (lipegfilgrastim) for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation
    Ivetta Danylesko
    Rina Sareli
    Nira Varda-Bloom
    Ronit Yerushalmi
    Noga Shem-Tov
    Hila Magen
    Avichai Shimoni
    Arnon Nagler
    International Journal of Hematology, 2021, 114 : 363 - 372
  • [37] Primary prophylaxis of febrile neutropenia using long-acting granulocyte colony-stimulating factors in female patients receiving dose-dense biweekly chemotherapy in the clinical routine.
    Kurbacher, Christian M.
    Kurbacher, A. Tabea
    Monreal, Katja
    Schweitzer, Claudia
    Sperling, Sandra
    Kolberg, Gabriele
    Kurbacher, Jutta A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] Review of practice patterns of primary granulocyte-colony stimulating factor prophylaxis and impact on febrile neutropenia rate and chemotherapy delivery in patients with early breast cancer treated with modern adjuvant chemotherapy.
    Mates, Mihaela
    Hopman, Wilma
    Altwairgi, Abdullah Khalaf
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Primary prophylaxis of febrile neutropenia in female patients receiving dose-dense biweekly chemotherapy in the clinical routine using long-acting granulocyte colony-stimulating factors is safe and effective
    Kurbacher, C. M.
    Kurbacher, A. T.
    Monreal, K.
    Herz, S.
    Sperling, S.
    Kurbacher, J. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 152 - 152
  • [40] Primary prophylaxis of febrile neutropenia using long-acting granulocyte colony-stimulating factors in female patients receiving dose-dense biweekly chemotherapy: A single-institution experience
    Kurbacher, C. M.
    Kurbacher, A. T.
    Monreal, K.
    Herz, S.
    Sperling, S.
    Kurbacher, J. A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S245 - S246
12345